Consultation: NICE 30-day TA – mirdametinib for plexiform neurofibromas

Following publication of a NICE 30-day TA for mirdametinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 2 to 17 years, we now seek comments on its implementation.

Comments are welcomed from across the system, including residents and patients of NENC. Comments will be returned to NTAG, and used to inform the final version that is presented for approval in NENC.

All comments will be reviewed but please do not expect a personal reply as we do not routinely reply to all comments. It is important to include any relevant evidence to back up any suggestions and please keep comments concise where possible. All comments received will shared unedited with the authors/working group who are developing the document to support the production of a final draft for approval.

Please note

1. The messages sent from this form are transmitted via our host’s web server. If you have any security concerns about this process you can send your comments/feedback using your own email client to nuth.nyrdtc.rxsupp@nhs.net.
2. This consultation will run for two weeks and closes at 5pm on Monday 19^th October 2026.

Name *

Email *

Email

Confirm Email

Job title *

Employer *

Locality

Are you responding on behalf of an organisation or as an individual? *

• On behalf of an organisation or organisational leader
• As an individual

Please specify who you are responding for, including job title and organisation as appropriate *

1a. Can your organisation provide access to mirdametinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 2 to 17 years, as recommended in NICE TA1192, within the implementation period? *

• Yes
• No (please specify below)
• Not applicable

1b. Is the proposed RAG status appropriate?

• Yes
• No (please specify below)

1c. Please provide detail on the barriers to providing access and how they might be addressed, and/or suggested changes to the proposed RAG status

1d. Please confirm that your Trust wishes to prescribe this drug for this indication as per the NICE TA – we require a yes or no answer from each Trust

• Yes
• No
• Not applicable

1e. Please provide an estimate of the annual number of patients who will have the treatment at your Trust – we require an answer from each Trust

—————————————————————————————————————

Do you have any additional comments?

Submit